BrainStorm repurchases warrants


BrainStorm Cell Therapeutics (BCLI) pays $600K to repurchase warrants to buy 5M shares of the company's common stock. The transaction was executed in preparation for the firm's uplisting to a national exchange.

Comments (3)
  • Tile
    , contributor
    Comments (119) | Send Message
     
    Go $BCLI. We need u on NYSE.
    29 May 2014, 08:43 AM Reply Like
  • Len Friedman
    , contributor
    Comments (93) | Send Message
     
    Recalling the warrants as was just made known, tells me the company is lining up its ducks in a row in order to be nimble---prior to obtaining a NASD listing. That could mean a couple of things:

     

    1. The company is very confident in its likely success as it pursues stated goals.

     

    2. The uplisting guarantees that a reverse split will be absolutely critical in advance of same.

     

    3. All eyes that aren't already on developments will now be, for certain. This is telling me loudly and clearly that the forthcoming news is expected to be startlingly good. I think this is a glimpse into very positive insider understandings and subsequent views. This is really all about timing.

     

    I currently hold 15,000 shares and am considering adding another 5,000 on the cheap. My sense is that the uplisting in conjunction with a reverse will result in a substantial rise in the publicly perceived value of this stock.....with people realizing this company is for real. The selloff typical of reverses will not be the case this time, imo.

     

    Is it time for BCLI to stand alongside CUR? That's a major question, of course...two very different approaches with each representing a potential blockbuster for anyone's portfolio. I hope others will chime in on this pick. \

     

    My opinions only in the above.

     

    Len
    29 May 2014, 10:48 AM Reply Like
  • Tile
    , contributor
    Comments (119) | Send Message
     
    @Len. Your assessment of $BCLI is correct. I currently hold 100 k shares average 26 cents. $CUR is also a very good company with a different approach in treating this merciless affliction. If you can't afford the current price of CUR, BCLI is the way to take you to the promise land. $BCLI has his own Ted HArada. P2 trial in the US should start probably at the end of this summer. As for the idea of a reverse split I don't like it too much. But if it comes to that, I will vote for it.
    Stay long.
    30 May 2014, 11:01 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs